News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.



Berlin, Germany, September 25, 2012 – The Supervisory Board of Epigenomics AG (ISIN: DE000A1K0516) and its current CEO Geert Walter Nygaard today agreed that Mr. Nygaard will leave the Executive Management Board of the company effective 30 September 2012.

The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board member of the company and this capacity also takes over the responsibility of acting CEO of Epigenomics, effective 1 October 2012. Dr. Uwe Staub, currently SVP R&D was promoted to COO and was granted “Prokura” (power of attorney). His duties will be expanded by the responsibility for
medical affairs and customer support.

The Supervisory Board thanks Mr. Nygaard for his commitment and contributions to Epigenomics over the last years.

– End of Ad hoc –

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386

Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.